<DOC>
	<DOCNO>NCT01041911</DOCNO>
	<brief_summary>The purpose study determine safe efficacious dose Euphorbia prostrata control per rectal bleeding patient first second degree hemorrhoid .</brief_summary>
	<brief_title>To Evaluate Dose Response 3 Doses Euphorbia Prostrata Patients With First Second Degree Hemorrhoids</brief_title>
	<detailed_description>Hemorrhoidal disease common entity general population clinical practice . The basic pathological factor hemorrhoid dilation anorectal venous plexus . In acute bleed internal hemorrhoid , one pathogenic process implicated stagnation stasis blood vascular plexus prolapse anal cushion . Euphorbia prostrata extract find antihemorrhoidal activity useful ameliorating sign symptom associated hemorrhoid .</detailed_description>
	<mesh_term>Hemorrhoids</mesh_term>
	<criteria>Adult subject able understand nature , significance scope clinical trial express accordingly agree participate study give write informed consent . Male female subject , least 18 year age diagnosis internal hemorrhoid ( first second degree ) confirm proctoscopic examination suffer uncomplicated untreated acute attack ( define acute onset per rectal bleeding within 3 day inclusion study , least one symptoms viz . pain , tenesmus , pruritus anal discharge ) . Except internal hemorrhoid ( first second degree ) , subject judge good general health , base medical history , physical examination , laboratory screening test . Pregnant lactate woman woman postpartum period 6 week . Women child bear potential agree remain abstinent use medically acceptable method contraception study therapy 4 week end study therapy . Subjects previously enrol study involve E. prostrata Dry Extract Subjects history permanent anal prolapse and/or anal fistula Subjects associate anal fissure and/or infective anal pathology . Subjects previous history surgery anorectal disease ( within 5 year ) procedure ( include limit injection sclerotherapy , rubber band ligation , photocoagulation , cryotherapy etc ) within 2 year enrolment trial . Subjects , opinion investigator , mentally incapacitate informed consent obtain . Subjects clinically significant comorbid condition opinion investigator could affect efficacy safety outcome study . Subjects clinically significant laboratory value hemoglobin , total leukocyte count , differential count , bleed time , clot time , PT/INR , aPTT/control , platelet count , SGOT , SGPT , alkaline phosphatase , total bilirubin , random blood sugar , serum cholesterol , blood urea , serum creatinine urine routine microscopic examination . Treatment follow inclusion previous one month venotropic , anticoagulant , anti platelet agent . Subjects aspirin 160 mg cardiovascular indication exclude trial . Treatment follow inclusion previous one week antiinflammatory analgesic agent . Other chronic medication use stable dosage least 2 week . Subjects current user illicit drug include `` recreational use '' history drug abuse within past 5 year . Subjects donate unit blood plasma participate another clinical study investigational agent within last 12 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Hemorrhoids</keyword>
</DOC>